VAR’s Latest Analyst Recommendations after Its 2Q17 Results
In a survey of nine brokerage companies on April 28, 2017, about 11.1% of these analysts rated VAR as a “buy,” and 77.8% rated it as a “hold.” Around 11.1% of analysts rated it as a “sell.”
On April 26, 2016, Varian Medical Systems (VAR) released its 2Q17 earnings. VAR beat consensus estimates for revenues in 2Q17 by ~0.8% and reported in-line earnings per share.
AbbVie’s (ABBV) Venclexta was approved by the FDA on April 11, 2016. AbbVie has also successfully launched Venclexta in Germany and France.
With 21% of newly diagnosed chronic lymphocytic leukemia (or CLL) patients opting for AbbVie’s (ABBV) Imbruvica, the drug attained a leading position in the frontline segment in 1Q17.
On April 4, 2017, AbbVie announced that the FDA had accepted for review the company’s application seeking approval for Imbruvica as a treatment option for patients suffering from cGVHD.
In 1Q17, Humira reported global revenues of around $4.1 billion, which is year-over-year operational growth of ~15.8%.
Of the 21 analysts covering AbbVie (ABBV) in April 2017, three rated the company as a “strong buy,” and six rated it as a “buy.”
For 1Q17, AbbVie (ABBV) reported revenues of about $6.5 billion, which equals year-over-year growth of ~9.7%.
Valuation multiple The EV-to-EBITDA (enterprise value to earnings before interest, tax, depreciation, and amortization) multiple is a good valuation metric for capital-intensive industries. It compares companies with various capital structures.…
Wall Street ratings Goldcorp (GG) reported a stronger-than-expected 1Q17, outlining a clear path to production growth and cost improvements in the quarter. Let’s look at Wall Street’s reaction after the company…
Goldcorp’s all-in sustaining costs In 1Q17, Goldcorp’s (GG) AISC (all-in sustaining costs) were $800 per ounce, a fall of 4.3% YoY (year-over-year). Investors should note that this fall in costs…
Sustained production growth After years of cutting back on their sustained capital expenditure, gold miners started to refocus on production growth in 2016 as gold prices (GLD) remained buoyant. Increased…
Goldcorp’s operational highlights Goldcorp’s (GG) gold revenue was 16% lower year-over-year (or YoY) in 1Q17, at $664 million. The decline was mainly due to a corresponding 16% fall in production during…
Fall in production Goldcorp’s (GG) gold production fell 16.4% year-over-year in 1Q17 to 655,000 ounces. The lower production was mainly due to the following: lower production at Red Lake due…
Goldcorp (GG) reported its 1Q17 results after the market closed on April 26, 2017. In this series, we’ll look at the company’s prospects based on its 1Q17 earnings and management’s comments.
The consensus 12-month target price for Stryker is $141, a ~3.5% return potential.
Stryker has registered strong revenues and earnings in the last few quarters.
Stryker (SYK) expects its 2017 revenue to witness a YoY (year-over-year) rise of 5.5%–6.5% on an organic basis.
Stryker (SYK) was trading at its 52-week high of $136.2 on April 27, 2017, with a 50-day moving average of $132 and a 200-day moving average of $122.3.
On April 25, 2017, Stryker (SYK) released its 1Q17 earnings. After the announcement, Stryker’s share price rose ~1.2%.